Company / Net Income
Ernexa Therapeutics Inc. Net Income History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$44.5M
FY2025
5-year range
-$44.5M / -$259.0K
FY2021-FY2025
Trend
-105.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income has fluctuated over the past 10 years, ranging from -$45M in FY2025 to -$259,000 in FY2019.
Based on SEC 10-K filings.
-$45M in FY2025.
Declined from -$25M to -$45M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, net income decreased 105.6% year-over-year.
- Peak net income was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$44.5M | -105.6% |
| FY2024 | -$21.7M | +11.8% |
| FY2023 | -$24.6M | -1100.7% |
| FY2020 | -$2.0M | -690.3% |
| FY2019 | -$259.0K | +76.0% |
| FY2018 | -$1.1M | +63.2% |
| FY2017 | -$2.9M | +59.5% |
| FY2016 | -$7.2M | -43.7% |
| FY2015 | -$5.0M | -377.7% |
| FY2014 | -$1.1M | -5.8% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026